Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies

Once-daily extended-release (ER) lorazepam was developed to reduce fluctuations in plasma levels compared with lorazepam immediate-release (IR) for short-term anxiety relief. Here we report a series of phase 1 randomized, open-label, multiperiod crossover studies characterizing ER lorazepam pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Sanjay J., Jean-Lys, Shedly, Phull, Rupinder, Yarasani, Rama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309101/
https://www.ncbi.nlm.nih.gov/pubmed/37335199
http://dx.doi.org/10.1097/JCP.0000000000001715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309101/
https://www.ncbi.nlm.nih.gov/pubmed/37335199
http://dx.doi.org/10.1097/JCP.0000000000001715

Ejemplares similares